Abstract
Aims
Antibody fragments have been shown to penetrate into the anterior chamber when applied to the cornea. The aim of this study was to investigate whether such fragments could penetrate into the vitreous cavity after topical administration to the ocular surface of rabbits.
Methods
An engineered single-chain variable-domain antibody fragment with specificity for an irrelevant rat determinant was applied as a 50 μl eye drop to the eyes of live rabbits at 20-min intervals over 12 h. Eye drops contained 0.8–1.1 mg/ml protein in a buffered salt solution supplemented with penetration and viscosity enhancers. Samples were collected by paracentesis from the vitreous cavity immediately postmortem. Antibody fragments in these samples were quantified by measuring the binding activity to specific antigen, using flow cytometry.
Results
Topically applied antibody fragments were detectable in the vitreous of rabbit eyes after 4–12 h but had cleared at 12 h following the final eye drop. Concentrations of the antibody fragment in the vitreous samples were estimated to be 50–150 ng/ml at 12 h. Penetration of the parental whole antibody into the vitreous was not observed.
Conclusion
Antibody fragments penetrate into the vitreous chamber of the rabbit eye after topical administration to the ocular surface. Such fragments may have therapeutic potential for diseases affecting the posterior segment.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Breedveld FC . Therapeutic monoclonal antibodies. Lancet 2000; 355: 735–740.
Hudson PJ, Souriau C . Engineered antibodies. Nat Med 2003; 9: 129–134.
Allansmith M, de Ramus A, Maurice D . The dynamics of IgG in the cornea. Invest Ophthalmol Vis Sci 1979; 18: 947–955.
Thiel MA, Coster DJ, Standfield SD, Brereton HM, Mavrangelos C, Zola H et al. Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 2002; 128: 67–74.
Morimoto K, Nakamura T, Morisaka K . Effect of medium-chain fatty acid salts on penetration of a hydrophilic compound and a macromolecular compound across rabbit corneas. Arch Int Pharmacodyn Ther 1989; 302: 18–26.
Sasaki H, Igarashi Y, Nagano T, Nishida K, Nakamura J . Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm Res 1995; 12: 1146–1150.
Acknowledgements
We acknowledge the expertise of A Yusim, G Turner and A Moisidis (all from CSL Ltd) in producing and purifying antibody fragments. Ms K Marshall provided expert assistance with experimental animals. This work was supported by the NH&MRC of Australia, the Ophthalmic Research Institute of Australia, and the Flinders Medical Centre Foundation. CSL Ltd has a proprietary interest in this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Williams, K., Brereton, H., Farrall, A. et al. Topically applied antibody fragments penetrate into the back of the rabbit eye. Eye 19, 910–913 (2005). https://doi.org/10.1038/sj.eye.6701669
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701669
Keywords
This article is cited by
-
Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits
Pharmaceutical Research (2024)
-
Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation
Pharmaceutical Research (2018)
-
Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye
Eye (2011)
-
Antibody-based immunosuppressive agents for corneal transplantation
Eye (2009)
